Featuring Dr. Felice Gersh on the Synergee Podcast with Lori Esarey and Kelly
For decades, women have been told conflicting stories about estrogen.
Some have heard that estrogen is essential for maintaining their health and quality of life. Others have been warned that hormone replacement therapy increases their risk of breast cancer. And for women who have already faced a breast cancer diagnosis, the conversation can become even more complicated.
So, does estrogen actually cause breast cancer?
The answer requires a deeper understanding of hormone biology, breast cancer risk, and the differences between women who have never had breast cancer and those who have.
In a thought-provoking episode of the Synergee Podcast, Lori Esarey and Kelly welcome Dr. Felice Gersh, an OB-GYN and integrative medicine physician, to explore estrogen, progesterone, breast cancer, and the complex decisions surrounding menopausal hormone therapy.
For Lori, this conversation is especially personal. As a breast cancer survivor, she understands what it means to weigh quality of life against concerns about recurrence—and how difficult it can be to ask questions when the answers are not straightforward.
Estrogen is much more than a reproductive hormone.
It plays important roles in bone health, the cardiovascular system, the brain, the genitourinary tract, and many other tissues throughout the body.
As women transition through menopause, declining estrogen levels can contribute to symptoms such as hot flashes, disrupted sleep, vaginal dryness, and changes in quality of life.
However, estrogen also influences the growth and activity of certain breast cells. This distinction is important.
Estrogen is not the sole cause of breast cancer, but estrogen signaling can stimulate the growth of hormone receptor-positive breast cancers.
Breast cancer develops through complex biological processes involving genetic changes, cellular regulation, hormonal influences, and other factors.
The relationship between estrogen exposure and breast cancer risk depends on many variables, including age, reproductive history, type and duration of hormone therapy, and individual risk factors.
Understanding these distinctions is essential before making decisions about treatment.
Not all breast cancers behave the same way.
Some breast cancers contain receptors that respond to estrogen, progesterone, or both. These are commonly described as:
Hormone receptor status helps guide treatment because estrogen signaling can promote the growth of many ER-positive tumors.
This is why endocrine therapies, including aromatase inhibitors and medications such as tamoxifen, are commonly used in appropriate patients to reduce recurrence risk.
It also explains why systemic menopausal hormone therapy is generally not recommended for women with a personal history of hormone receptor-positive breast cancer.
For survivors, hormone therapy decisions require particularly careful evaluation because the evidence about recurrence risk is limited and some clinical trials have demonstrated increased recurrence with systemic hormone therapy.
One of the most influential events in the history of menopausal hormone therapy was the Women’s Health Initiative (WHI).
When results from a major WHI hormone therapy trial were publicized in 2002, concerns about breast cancer and other health risks dramatically changed prescribing practices.
But the WHI was not a single study of every hormone formulation.
One major trial evaluated oral conjugated equine estrogens combined with medroxyprogesterone acetate in women with a uterus. Another evaluated estrogen alone in women who had undergone hysterectomy.
These trials produced different breast cancer findings.
The combined estrogen-progestin regimen was associated with an increased incidence of breast cancer, while the estrogen-alone trial showed different results in its specific study population.
These findings should not be interpreted as proving that all hormone regimens carry identical risks.
At the same time, differences between formulations do not establish that bioidentical hormones are free of breast cancer risk.
The important lesson is that hormone therapy must be evaluated according to the specific medication, dose, route, duration, and patient population being studied.
The term bioidentical describes hormones that have the same molecular structure as hormones produced by the human body.
FDA-approved bioidentical hormone options include certain estradiol products and oral micronized progesterone.
Compounded bioidentical hormone preparations are also available, but they are not
FDA-approved as finished products and generally have less standardized evidence regarding safety, effectiveness, and consistency.
Transdermal estradiol, oral estrogen, micronized progesterone, and synthetic progestins can differ in their pharmacologic effects and risk profiles.
However, an important distinction must be made:
Bioidentical does not automatically mean safer for someone with a history of breast cancer.
In particular, there is insufficient evidence to conclude that systemic bioidentical hormone therapy is safe after hormone receptor-positive breast cancer.
Women deserve accurate information about these differences without oversimplified promises or fear-based messaging.
For Lori, the subject of hormone therapy is more than a clinical discussion.
As a breast cancer survivor, she has experienced the uncertainty, emotional weight, and difficult decisions that can accompany a diagnosis.
In this Synergee Podcast conversation, Lori shares her experience of reconsidering hormone therapy after breast cancer and the challenges she encountered discussing that decision with her traditional healthcare providers.
Even with her extensive clinical background, navigating these conversations was not easy.
Her experience raises an important issue: Women should feel comfortable asking questions about their symptoms, treatment options, quality of life, and personal values.
That does not mean every treatment choice carries the same degree of safety.
It means that informed decisions require honest discussions about what is known, what remains uncertain, and how the evidence applies to the individual.
For women with a history of breast cancer, especially hormone receptor-positive disease, decisions about systemic hormone therapy should involve their oncology team and an experienced menopause clinician.
This is one of the most challenging areas of menopausal medicine.
Systemic hormone therapy can be effective for menopausal symptoms in many women without a history of breast cancer, but the risk-benefit balance changes substantially after a breast cancer diagnosis.
Randomized evidence in breast cancer survivors has raised concerns about increased recurrence risk with systemic hormone therapy.
There are also important gaps in the research, particularly regarding newer formulations and specific survivor populations.
A lack of definitive evidence for a particular hormone formulation is not proof of safety.
For women experiencing significant menopausal symptoms after breast cancer, nonhormonal therapies and supportive lifestyle strategies are often considered first.
For selected women experiencing genitourinary symptoms, low-dose vaginal estrogen may be discussed after nonhormonal measures have been insufficient, with shared decision-making involving the appropriate clinicians. This is different from systemic hormone therapy.
The goal should be to address symptoms while respecting the individual’s cancer history and the best available evidence.
One of the important themes explored in this episode is the broader role of whole-person health.
Hormones do not function in isolation.
Metabolic health, sleep quality, physical activity, stress, and body composition all influence a woman’s overall well-being during menopause and beyond.
At Total Nutrition & Therapeutics, these are foundational areas of our approach.
Metabolic Health
Insulin resistance, excess visceral fat, and metabolic dysfunction can influence long-term health and may be associated with certain cancer-related risks.
Supporting healthy blood sugar regulation, improving nutritional quality, and addressing metabolic risk factors are meaningful parts of preventive care.
Sleep and Recovery
Poor sleep affects energy, mood, cognitive performance, appetite regulation, and daily function.
For women navigating menopause or breast cancer survivorship, identifying and addressing sleep disturbances can be an important quality-of-life intervention.
Movement and Muscle Health
Regular physical activity and resistance training help preserve strength, mobility, metabolic health, and independence.
Physical activity is also associated with improved outcomes in breast cancer survivorship, although it cannot eliminate recurrence risk.
Stress and Emotional Well-Being
A breast cancer diagnosis can create lasting emotional and psychological stress.
Supportive relationships, counseling when needed, restorative routines, and stress-management practices can contribute to quality of life.
These strategies are valuable whether or not hormone therapy is appropriate.
Importantly, lifestyle interventions complement—not replace—recommended cancer treatments and surveillance.
Whether you’re approaching menopause, have a family history of breast cancer, or are navigating survivorship, meaningful conversations with your healthcare team should include questions such as:
The purpose of asking questions is not to arrive at a predetermined answer.
It’s to ensure that your care reflects the available evidence, your medical history, and your priorities.
At Total Nutrition & Therapeutics, our philosophy is rooted in education, individualized care, and helping clients become active participants in their health journey.
We believe women deserve to understand not only their symptoms, but also the physiology and risk factors that may be contributing to them.
That means looking at nutrition, metabolic function, body composition, sleep, physical activity, stress, and the broader clinical picture.
It also means recognizing the limits of what we know.
For women facing complex decisions about hormone therapy and breast cancer, collaboration among healthcare professionals is essential.
Our goal is not to replace oncology care or promise that one treatment is right for everyone.
Our goal is to help individuals become better informed, ask meaningful questions, and build a stronger foundation for lifelong health.
Does estrogen cause breast cancer?
The relationship is more complex than a simple yes or no.
Estrogen plays essential roles in normal physiology, but it can also stimulate the growth of hormone-sensitive breast cancer cells. Hormone therapy risks vary by formulation, patient population, and individual history.
For women who have experienced breast cancer, particularly hormone receptor-positive disease, the conversation requires additional caution.
And for every woman, the opportunity to ask questions and receive thoughtful, evidence-informed answers matters.
Your health history is unique. Your concerns deserve to be heard. And your decisions deserve to be informed.
Watch the Full Synergee Podcast Episode
Join Lori Esarey, Kelly, and Dr. Felice Gersh for an important conversation about estrogen, progesterone, breast cancer risk, and the challenges of making informed decisions about hormone therapy.
Watch: Does Estrogen Cause Breast Cancer? Dr. Felice Gersh on Hormone Therapy and Risk
At Total Nutrition & Therapeutics, we help individuals explore the connections between nutrition, metabolic wellness, healthy aging, and overall well-being.
If you’re ready to better understand your health and develop a more individualized approach to wellness, we invite you to connect with our team.
Total Nutrition & Therapeutics — Educate. Empower. Transform.
Medical disclaimer: This article is intended for educational purposes and does not replace individualized medical advice. Systemic menopausal hormone therapy is generally not recommended for women with a personal history of breast cancer, especially hormone receptor-positive disease. Treatment decisions should be made with qualified healthcare professionals, including an oncology team when applicable.
Ready to start your journey with Total Nutrition and Therapeutics?
Visit Store